Literature DB >> 18027980

Mechanism-based inhibition of Sir2 deacetylases by thioacetyl-lysine peptide.

Brian C Smith1, John M Denu.   

Abstract

Sir2 protein deacetylases (or sirtuins) catalyze NAD+-dependent conversion of epsilon-amino-acetylated lysine residues to deacetylated lysine, nicotinamide, and 2'-O-acetyl-ADP-ribose. Small-molecule modulation of sirtuin activity might treat age-associated diseases, such as type II diabetes, obesity, and neurodegenerative disorders. Here, we have evaluated the mechanisms of sirtuin inhibition of histone peptides containing thioacetyl or mono-, di-, and trifluoroacetyl groups at the epsilon-amino of lysine. Although all substituted peptides yielded inhibition of the deacetylation reaction, the thioacetyl-lysine peptide exhibited exceptionally potent inhibition of sirtuins Sirt1, Sirt2, Sirt3, and Hst2. Using Hst2 as a representative sirtuin, the trifluoroacetyl-lysine peptide displayed competitive inhibition with acetyl-lysine substrate and yielded an inhibition constant (Kis) of 4.8 microM, similar to its Kd value of 3.3 microM. In contrast, inhibition by thioacetyl-lysine peptide yielded an inhibition constant (Kis) of 0.017 microM, 280-fold lower than its Kd value of 4.7 microM. Examination of thioacetyl-lysine peptide as an alternative sirtuin substrate revealed conserved production of deacetylated peptide and 1'-SH-2'-O-acetyl-ADP-ribose. Pre-steady-state and steady-state analysis of the thioacetyl-lysine peptide showed rapid nicotinamide formation (4.5 s-1) but slow overall turnover (0.0024 s-1), indicating that the reaction stalled at an intermediate after nicotinamide formation. Mass spectral analysis yielded a novel species (m/z 1754.3) that is consistent with an ADP-ribose-peptidyl adduct (1'-S-alkylamidate) as the stalled intermediate. Additional experiments involving solvent isotope effects, general base mutational analysis, and density functional calculations are consistent with impaired 2'-hydroxyl attack on the ADP-ribose-peptidyl intermediate. These results have implications for the development of mechanism-based inhibitors of Sir2 deacetylases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18027980     DOI: 10.1021/bi7013294

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  52 in total

1.  Thiosuccinyl peptides as Sirt5-specific inhibitors.

Authors:  Bin He; Jintang Du; Hening Lin
Journal:  J Am Chem Soc       Date:  2012-01-20       Impact factor: 15.419

2.  Mechanism-based affinity capture of sirtuins.

Authors:  Yana Cen; Jessica N Falco; Ping Xu; Dou Yeon Youn; Anthony A Sauve
Journal:  Org Biomol Chem       Date:  2010-12-24       Impact factor: 3.876

3.  A mechanism-based potent sirtuin inhibitor containing Nε-thiocarbamoyl-lysine (TuAcK).

Authors:  Brett M Hirsch; Yujun Hao; Xiaopeng Li; Chrys Wesdemiotis; Zhenghe Wang; Weiping Zheng
Journal:  Bioorg Med Chem Lett       Date:  2011-06-22       Impact factor: 2.823

4.  Highly dissociative and concerted mechanism for the nicotinamide cleavage reaction in Sir2Tm enzyme suggested by ab initio QM/MM molecular dynamics simulations.

Authors:  Po Hu; Shenglong Wang; Yingkai Zhang
Journal:  J Am Chem Soc       Date:  2008-12-10       Impact factor: 15.419

5.  Genomewide screen for negative regulators of sirtuin activity in Saccharomyces cerevisiae reveals 40 loci and links to metabolism.

Authors:  Ryan M Raisner; Hiten D Madhani
Journal:  Genetics       Date:  2008-08-09       Impact factor: 4.562

6.  Measurement of sirtuin enzyme activity using a substrate-agnostic fluorometric nicotinamide assay.

Authors:  Basil P Hubbard; David A Sinclair
Journal:  Methods Mol Biol       Date:  2013

Review 7.  Sirtuin catalysis and regulation.

Authors:  Jessica L Feldman; Kristin E Dittenhafer-Reed; John M Denu
Journal:  J Biol Chem       Date:  2012-10-18       Impact factor: 5.157

Review 8.  Small molecule SIRT1 activators for the treatment of aging and age-related diseases.

Authors:  Basil P Hubbard; David A Sinclair
Journal:  Trends Pharmacol Sci       Date:  2014-01-16       Impact factor: 14.819

9.  A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.

Authors:  Hui Jing; Jing Hu; Bin He; Yashira L Negrón Abril; Jack Stupinski; Keren Weiser; Marisa Carbonaro; Ying-Ling Chiang; Teresa Southard; Paraskevi Giannakakou; Robert S Weiss; Hening Lin
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

Review 10.  Sirtuin inhibitors as anticancer agents.

Authors:  Jing Hu; Hui Jing; Hening Lin
Journal:  Future Med Chem       Date:  2014-05       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.